EGFR and squamous cell carcinoma: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (e.g., erlotinib, gefitinib, and afatinib), employed as first-line treatments for advanced NSCLC, demonstrate pronounced efficacy primarily against histotypes other than squamous carcinoma [17].